Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01567826 · ClinicalTrials.gov registry record · Phase 4
Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy
A Phase 4 study of Coronary Artery Disease, sponsored by Annapoorna Kini.
- Completed
- Registry status
- Phase 4
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT01567826 is a Phase 4 study of Coronary Artery Disease that has completed, run by Annapoorna Kini. The registered enrollment target is 87 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01567826, a Phase 4 study of Coronary Artery Disease, has completed, sponsored by Annapoorna Kini.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will assess the regression of yellow plaque content of the lipid pool after aggressive lipid therapy by utilizing NIR spectroscopy. Statin therapy using Rosuvastatin 10-40 mg will be compared to the statin therapy of either Atorvastatin or Simvastatin. This is a single site study. A total of 100 subjects will randomized, of which 40 will receive intensive lipid therapy (Rosuvastatin 40mg) and 40 will receive standard care lipid lowering therapy.
Conditions Studied
Interventions
- DRUG standard of care lipid therapy
- DRUG Aggressive lipid therapy
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01567826
The ClinicalTrials.gov registry entry for NCT01567826 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (93% lower). The listed sponsor is Annapoorna Kini, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which standard of care lipid therapy is the first listed.
NCT01567826 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01567826 about?
NCT01567826 is a clinical study titled "Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy". The study will assess the regression of yellow plaque content of the lipid pool after aggressive lipid therapy by utilizing NIR spectroscopy. Statin therapy using Rosuvastatin 10-40 mg will be compared to the statin therapy of either Atorvastatin or Simvastatin. This is a single site study. A total ...
What is the current status of trial NCT01567826?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 87 participants. The study started on 2010-05. Estimated completion is 2012-02.
What conditions does trial NCT01567826 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT01567826?
The interventions under investigation include: standard of care lipid therapy (DRUG), Aggressive lipid therapy (DRUG).
Who is sponsoring clinical trial NCT01567826?
This trial is sponsored by Annapoorna Kini, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01567826 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
RECRUITING · Phase 4
-
The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial
RECRUITING · Phase 4
-
Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study
RECRUITING · Phase 4
-
Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention
RECRUITING · Phase 4
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine
RECRUITING · Phase 4
-
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.